OBJECTIVE: Glomerulonephritis (GN) is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but tools for early detection of renal involvement are imperfect. We investigated 4 urinary proteins as markers of active renal AAV: alpha-1 acid glycoprotein (AGP), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL). METHODS: Patients with active renal AAV (n = 20), active nonrenal AAV (n = 16), and AAV in longterm remission (n = 14) were identified within a longitudinal cohort. Urinary biomarker concentrations (by ELISA) were normalized for urine creatinine. Marker levels during active AAV were compared to baseline remission levels (from 1-4 visits) for each patient. Areas under receiver-operating characteristic curves (AUC), sensitivities, specificities, and likelihood ratios (LR) comparing disease states were calculated. RESULTS: Baseline biomarker levels varied among patients. All 4 markers increased during renal flares (p < 0.05). MCP-1 discriminated best between active renal disease and remission: a 1.3-fold increase in MCP-1 had 94% sensitivity and 89% specificity for active renal disease (AUC = 0.93, positive LR 8.5, negative LR 0.07). Increased MCP-1 also characterized 50% of apparently nonrenal flares. Change in AGP, KIM-1, or NGAL showed more modest ability to distinguish active renal disease from remission (AUC 0.71-0.75). Hematuria was noted in 83% of active renal episodes, but also 43% of nonrenal flares and 25% of remission samples. CONCLUSION: Either urinary MCP-1 is not specific for GN in AAV, or it identifies early GN not detected by standard assessment and thus has potential to improve care. A followup study with kidney biopsy as the gold standard is needed.
OBJECTIVE:Glomerulonephritis (GN) is common in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but tools for early detection of renal involvement are imperfect. We investigated 4 urinary proteins as markers of active renal AAV: alpha-1 acid glycoprotein (AGP), kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL). METHODS:Patients with active renal AAV (n = 20), active nonrenal AAV (n = 16), and AAV in longterm remission (n = 14) were identified within a longitudinal cohort. Urinary biomarker concentrations (by ELISA) were normalized for urine creatinine. Marker levels during active AAV were compared to baseline remission levels (from 1-4 visits) for each patient. Areas under receiver-operating characteristic curves (AUC), sensitivities, specificities, and likelihood ratios (LR) comparing disease states were calculated. RESULTS: Baseline biomarker levels varied among patients. All 4 markers increased during renal flares (p < 0.05). MCP-1 discriminated best between active renal disease and remission: a 1.3-fold increase in MCP-1 had 94% sensitivity and 89% specificity for active renal disease (AUC = 0.93, positive LR 8.5, negative LR 0.07). Increased MCP-1 also characterized 50% of apparently nonrenal flares. Change in AGP, KIM-1, or NGAL showed more modest ability to distinguish active renal disease from remission (AUC 0.71-0.75). Hematuria was noted in 83% of active renal episodes, but also 43% of nonrenal flares and 25% of remission samples. CONCLUSION: Either urinary MCP-1 is not specific for GN in AAV, or it identifies early GN not detected by standard assessment and thus has potential to improve care. A followup study with kidney biopsy as the gold standard is needed.
Authors: Vishal S Vaidya; Victoria Ramirez; Takaharu Ichimura; Norma A Bobadilla; Joseph V Bonventre Journal: Am J Physiol Renal Physiol Date: 2005-09-20
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: T Wada; K Furuichi; C Segawa-Takaeda; M Shimizu; N Sakai; S I Takeda; K Takasawa; H Kida; K I Kobayashi; N Mukaida; Y Ohmoto; K Matsushima; H Yokoyama Journal: Kidney Int Date: 1999-09 Impact factor: 10.612
Authors: Alicia Rodriguez-Pla; Roscoe L Warner; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Kent J Johnson; Peter A Merkel; Paul A Monach Journal: J Rheumatol Date: 2019-09-01 Impact factor: 4.666
Authors: A W S de Souza; W H Abdulahad; P Sosicka; J Bijzet; P C Limburg; C A Stegeman; M Bijl; J Westra; C G M Kallenberg Journal: Clin Exp Immunol Date: 2014-11 Impact factor: 4.330
Authors: Adam D Morris; Camilo L M Morais; Kássio M G Lima; Daniel L D Freitas; Mark E Brady; Ajay P Dhaygude; Anthony W Rowbottom; Francis L Martin Journal: Sci Rep Date: 2021-05-11 Impact factor: 4.379
Authors: Vincent P O'Reilly; Limy Wong; Claire Kennedy; Louise A Elliot; Shane O'Meachair; Alice Marie Coughlan; Eoin C O'Brien; Michelle M Ryan; Diego Sandoval; Emma Connolly; Gerjan J Dekkema; Jiaying Lau; Wayel H Abdulahad; Jan-Stephan F Sanders; Peter Heeringa; Colm Buckley; Cathal O'Brien; Stephen Finn; Clemens D Cohen; Maja T Lindemeyer; Fionnuala B Hickey; Paul V O'Hara; Conleth Feighery; Sarah M Moran; George Mellotte; Michael R Clarkson; Anthony J Dorman; Patrick T Murray; Mark A Little Journal: J Am Soc Nephrol Date: 2016-03-03 Impact factor: 10.121
Authors: Sarah M Moran; Paul A Monach; Lina Zgaga; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine Sreih; Jason Wyse; Steven R Ytterberg; Peter A Merkel; Mark A Little Journal: Nephrol Dial Transplant Date: 2020-02-01 Impact factor: 7.186